PMS2

Chr 7AR

PMS1 homolog 2, mismatch repair system component

Also known as: HNPCC4, LYNCH4, MLH4, MMRCS4, PMS-2, PMS2CL, PMSL2

The protein encoded by this gene is a key component of the mismatch repair system that functions to correct DNA mismatches and small insertions and deletions that can occur during DNA replication and homologous recombination. This protein forms heterodimers with the gene product of the mutL homolog 1 (MLH1) gene to form the MutL-alpha heterodimer. The MutL-alpha heterodimer possesses an endonucleolytic activity that is activated following recognition of mismatches and insertion/deletion loops by the MutS-alpha and MutS-beta heterodimers, and is necessary for removal of the mismatched DNA. There is a DQHA(X)2E(X)4E motif found at the C-terminus of the protein encoded by this gene that forms part of the active site of the nuclease. Mutations in this gene have been associated with hereditary nonpolyposis colorectal cancer (HNPCC; also known as Lynch syndrome) and Turcot syndrome. [provided by RefSeq, Apr 2016]

Primary Disease Associations & Inheritance

Lynch syndrome 4MIM #614337
Mismatch repair cancer syndrome 4MIM #619101
AR
592
ClinVar variants
72
Pathogenic / LP
0.00
pLI score
12
Active trials
Clinical SummaryPMS2
🧬
Gene-Disease Validity (ClinGen)
Lynch syndrome · ADDefinitive

Definitive — sufficient evidence for diagnostic panels

3 total gene-disease associations curated

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
72 Pathogenic / Likely Pathogenic· 224 VUS of 592 total submissions
💊
Clinical Trials
12 active or recruiting trials — potential therapeutic options may be available

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?LOEUF (Loss-of-function Observed/Expected Upper bound Fraction) is the upper bound of the 90% CI for LoF OE — the preferred gnomAD v4 metric. Lower = more intolerant to LoF. LOEUF < 0.35 = highly constrained.
1.27LOEUF
pLI 0.000
Z-score 0.15
OE 0.98 (0.761.27)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint?Missense Z-score: standard deviations fewer missense variants observed vs. expected. Z > 3.09 (p < 0.001) = gene does not tolerate missense variation. OE missense < 0.6 is also considered constrained.
-0.56Z-score
OE missense 1.07 (1.001.16)
502 obs / 468.1 exp
Tolerant

Tolerant to missense variation

Observed / Expected Ratios?Shaded band = 90% confidence interval. Vertical tick = point estimate. Grey threshold line = gnomAD constraint cutoff for that variant class.
LoF OE?Ratio of observed to expected LoF variants. Upper CI bound (LOEUF) ≤ 0.35 = strong LoF constraint signal.0.98 (0.761.27)
00.351.4
Missense OE?Ratio of observed to expected missense variants. OE ≤ 0.6 = fewer missense variants than expected by chance.1.07 (1.001.16)
00.61.4
Synonymous OE?Control metric — synonymous variants are largely neutral and expected near OE = 1.0. Significant deviation may indicate annotation issues.1.10
01.21.6
LoF obs/exp: 41 / 42.0Missense obs/exp: 502 / 468.1Syn Z: -1.07

ClinVar Variant Classifications

592 submitted variants in ClinVar

Classification Summary

Pathogenic55
Likely Pathogenic17
VUS224
Likely Benign175
Benign116
Conflicting5
55
Pathogenic
17
Likely Pathogenic
224
VUS
175
Likely Benign
116
Benign
5
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
33
0
22
0
55
Likely Pathogenic
12
0
5
0
17
VUS
4
190
29
1
224
Likely Benign
4
16
94
61
175
Benign
0
4
44
68
116
Conflicting
5
Total53210194130592

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

PMS2 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Gene2Phenotype Curations

PMS2-related Lynch syndrome

definitive
ADLoss Of FunctionAbsent Gene Product
SkinCancer
G2P ↗

PMS2-related constitutional mismatch repair deficiency syndrome (CMMRD)

definitive
ARLoss Of FunctionAbsent Gene Product
Dev. DisordersSkinCancer
G2P ↗

Gene2Phenotype curations · DECIPHER consortium patient cohort (public variants) · deciphergenomics.org

OMIM — Genotype-Phenotype Relationships

1 OMIM entry

Lynch syndrome 4

MIM #614337

Molecular basis of disorder known

Mismatch repair cancer syndrome 4

MIM #619101

Molecular basis of disorder known

Autosomal recessive
📖
GeneReview available — PMS2
Authoritative clinical overview · NCBI Bookshelf · Recommended first read
Open GeneReview ↗
Clinical Literature
Landmark / reviewRecent case evidence

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Lynch Syndrome

Effect of Chemoprevention by Low-dose Aspirin of New or Recurrent Colorectal Adenomas in Patients With Lynch Syndrome

ACTIVE NOT RECRUITING
NCT02813824Phase PHASE3Assistance Publique - Hôpitaux de ParisStarted 2017-11-14
Acetylsalicylic acid lysinate 300 mgPlacebo (for Aspirin 300)Acetylsalicylic acid lysinate 100 mg
Prostate Cancer

Analysing Outcomes After Prostate Cancer Diagnosis and Treatment in Carriers of Rare Germline Mutations

RECRUITING
NCT02705846Institute of Cancer Research, United KingdomStarted 2014-09
Observation of treatment outcomes via Questionnaire
Polycythemia VeraEssential ThrombocythaemiaMyelofibrosis

Prevalence Of Germline Gene Mutations In Patients With Myeloproliferative Neoplasms With Family History

NOT YET RECRUITING
NCT06923670Phase NAFondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2025-05-21
NGS testingNGS analysis for mutations in genes involved in familial predisposition to hematological malignancies
Prostate CancerBRCA MutationMismatch Repair Gene Mutation

The GENPET Study - An Imaging Study of FCH-PET-CT in Men With Prostate Cancer and a DNA Repair Gene Mutation.

RECRUITING
NCT05097274Institute of Cancer Research, United KingdomStarted 2015-10-15
MRI pelvis or CT imaging under clinical management for Pr CaWhole body bone scan imagingPET-CT imaging
Solid TumorAdvanced Solid TumorMetastatic Cancer

KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II

RECRUITING
NCT05525858Seoul National University Bundang HospitalStarted 2022-09-28
AlectinibAtezolizumabErlotinib
Pancreas CancerExosomesExtracellular Vesicles

ExoLuminate Study for Early Detection of Pancreatic Cancer

RECRUITING
NCT05625529Biological DynamicsStarted 2022-12-19
Lynch SyndromeColorectal Cancer (CRC)

Predictive Value of PREMM5, MMRpredict, and Universal Tumor Screening for Lynch Syndrome in Vietnam

NOT YET RECRUITING
NCT06863038University of Medicine and Pharmacy at Ho Chi Minh CityStarted 2025-03-17
Lynch SyndromeLynch Syndrome ILynch Syndrome II

Lynch Syndrome X-Talk of Enteral Mucosa With Immune System

RECRUITING
NCT06708429San Raffaele UniversityStarted 2023-06-01
LYNX EYE (Lynch syndrome X-Talk of Enteral mucosa with Immune System)
BRCA-Mutated Ovarian CarcinomaBRIP1 Gene MutationMSH2 A636P

Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome

ACTIVE NOT RECRUITING
NCT04009148NYU Langone HealthStarted 2019-03-01
CASCADE genetic screening
Lynch SyndromeEndometrial Cancer

EC_ItaLynch: Mainstreaming the Diagnosis of Lynch Syndrome

NOT YET RECRUITING
NCT06501417Fondazione Policlinico Universitario Agostino Gemelli IRCCSStarted 2024-08-01
mainstreaming
Lynch SyndromeLynch Syndrome ILynch Syndrome II

Videocapsule Endoscopy in Lynch Syndrome

RECRUITING
NCT05704010Phase NASan Raffaele UniversityStarted 2018-11-01
Video capsule endoscopy
Colorectal CancerLynch SyndromeHereditary Colorectal Cancer

Prospective Multicenter Registry Study to Assess the Frequency of Lynch Syndrome Among Patients With Colorectal Cancer

RECRUITING
NCT05495776State Scientific Centre of Coloproctology, Russian FederationStarted 2022-08-01